[1]
|
Seyedian, S.S., Nokhostin, F. and Malamir, M.D. (2019) A Review of the Diagnosis, Prevention, and Treatment Meth-ods of Inflammatory Bowel Disease. Journal of Medicine and Life, 12, 113-122.
https://doi.org/10.25122/jml-2018-0075
|
[2]
|
Zhang, Y.Z. and Li, Y.Y. (2014) Inflammatory Bowel Disease: Path-ogenesis. World Journal of Gastroenterology, 20, 91-99. https://doi.org/10.3748/wjg.v20.i1.91
|
[3]
|
郭云萍, 孙哲, 连海峰. 瘦素在炎症性肠病中作用的研究进展[J]. 国际医药卫生导报, 2021, 27(23): 3643-3647.
|
[4]
|
李娜, 叶梅. 炎症性肠病生物制剂治疗的前沿进展[J]. 医学新知, 2022, 32(4): 310-320.
|
[5]
|
程小韵, 李景南. 生物制剂和小分子药物在炎症性肠病中的应用现状[J]. 中华内科杂志, 2021, 60(4): 376-379.
|
[6]
|
童锦禄, 冉志华. 生物制剂双靶治疗炎症性肠病的研究现状[J]. 中华炎性肠病杂志, 2022, 6(2): 106-109.
|
[7]
|
Tighe, D. and McNamara, D. (2017) Clinical Impact of Immunomonitoring in the Treatment of Inflammatory Bowel Disease. World Journal of Gas-troenterology, 23, 414-425. https://doi.org/10.3748/wjg.v23.i3.414
|
[8]
|
中国医药教育协会炎症性肠病专业委员会. 中国炎症性肠病生物制剂治疗专家建议(试行) [J]. 中华消化病与影像杂志(电子版), 2021, 11(6): 244-256.
|
[9]
|
Atreya, I. and Neurath, M.F. (2008) Azathioprine in Inflammatory Bowel Disease: Improved Molecular Insights and Resulting Clinical Implications. Expert Review of Gastroenterology & Hepatology, 2, 23-34.
https://doi.org/10.1586/17474124.2.1.23
|
[10]
|
刘爱玲, 吕红, 钱家鸣. 英夫利西单抗治疗炎症性肠病失应答[J]. 协和医学杂志, 2015(2): 140-145.
|
[11]
|
Papamichael, K., Lin, S., Moore, M., et al. (2019) Infliximab in Inflammatory Bowel Disease. Therapeutic Advances in Chronic Disease, 10, 1-15. https://doi.org/10.1177/2040622319838443
|
[12]
|
Seow, C.H., Newman, A., Irwin, S.P., et al. (2010) Trough Se-rum Infliximab: A Predictive Factor of Clinical Outcome for Infliximab Treatment in Acute Ulcerative Colitis. Gut, 59, 49-54. https://doi.org/10.1136/gut.2009.183095
|
[13]
|
贺小露, 周青, 黄晓晖. 英夫利昔单抗治疗炎症性肠病失应答的研究进展[J]. 实用药物与临床, 2021, 24(5): 477-480.
|
[14]
|
Sultan, K.S., Berkowitz, J.C. and Khan, S. (2017) Combination Therapy for Inflammatory Bowel Disease. World Journal of Gastrointestinal Pharmacology and Thera-peutics, 8, 103-113. https://doi.org/10.4292/wjgpt.v8.i2.103
|
[15]
|
Panaccione, R., Ghosh, S., Middleton, S., et al. (2014) Combination Therapy with Infliximab and Azathioprine Is Superior To monotherapy with Either Agent in Ulcera-tive Colitis. Gastroenterology, 146, 392-400.
https://doi.org/10.1053/j.gastro.2013.10.052
|
[16]
|
张明, 王新颖. 组织愈合在炎症性肠病诊治中的应用[J]. 中华消化杂志, 2017, 37(1): 68-70.
|
[17]
|
郝艳萍, 韩靓, 滕圣智, 王琳. 生物制剂联合免疫抑制剂对炎症性肠病患者营养状况及炎症反应的影响[J]. 中外医学研究, 2022, 20(18): 43-46.
|
[18]
|
Takač, B., Mihaljević, S., Glavaš-Obrovac, L., et al. (2020) Interactions among Interleukin-6, C-Reactive Protein and Interleukin-6 (-174) G/C Polymorphism in the Pathogenesis of Crohn’s Disease and Ulcerative Colitis. Acta Clinica Croatica, 59, 67-80. https://doi.org/10.20471/acc.2020.59.01.09
|
[19]
|
郭家英, 韩真. 免疫抑制剂联合生物制剂在炎症性肠病治疗中的新进展[J]. 沈阳医学院学报, 2018, 20(5): 455-459, 474.
|
[20]
|
Lucaciu, L.A., Ilieș, M., Vesa, C., et al. (2021) Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease. Journal of Personalized Medicine, 11, Article No. 1130. https://doi.org/10.3390/jpm11111130
|
[21]
|
陈佩玲, 谢伦芳. 克罗恩病患者应用英夫利西单抗的输液不良反应[J]. 医药导报, 2020, 39(12): 1756-1759.
|
[22]
|
李峰, 晋红中. 119例英夫利西单抗不良反应的文献分析[J]. 中国药物警戒, 2016, 13(4): 229-232.
|
[23]
|
Sorcha, O., Kavinderjit, S.N. and Alan, C.M. (2014) Antibodies to Infliximab and Risk of Infusion Reactions in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. In-flammatory Bowel Diseases, 20, 1-6. https://doi.org/10.1097/01.MIB.0000436951.80898.6d
|
[24]
|
郑彦丰. 免疫抑制剂在炎症性肠病中对英夫利昔免疫原性影响的meta分析[D]: [硕士学位论文]. 汕头: 汕头大学, 2016.
|
[25]
|
饶艳霞, 陈洁. 炎症性肠病与claudin蛋白[J]. 中华儿科杂志, 2011, 49(9): 717-719.
|
[26]
|
陈静, 吴军. 肠内营养对营养不良的溃疡性结肠炎免疫功能及生存质量的影响[J]. 安徽医学, 2020, 41(12): 1454-1457.
|
[27]
|
赵锋. 硫唑嘌呤联合英夫利西单抗对炎性肠病患者免疫功能与营养状态的影响[J]. 现代医学与健康研究电子杂志, 2021, 5(5): 55-57.
|
[28]
|
许馨文, 周群燕, 陈中霞, 等. 生物制剂治疗中重度溃疡性结肠炎的研究进展[J]. 胃肠病学, 2021, 26(6): 363-367.
|
[29]
|
Lichtenstein, G.R., Feagan, B.G., Cohen, R.D., et al. (2014) Drug Therapies and the Risk of Ma-lignancy in Crohn’s Disease: Results from the TREAT™ Registry. The American Journal of Gastroenterology, 109, 212-223.
https://doi.org/10.1038/ajg.2013.441
|
[30]
|
Matsuoka, K., Kobayashi, T., Ueno, F., et al. (2018) Evidence-Based Clinical Practice Guidelines for Inflammatory Bowel Disease. Journal of Gastroenterology, 53, 305-353. https://doi.org/10.1007/s00535-018-1439-1
|
[31]
|
刘四方, 刘晓红. 硫唑嘌呤/6-巯嘌呤治疗炎性肠病前检测硫嘌呤甲基转移酶的临床意义[J]. 基础医学与临床, 2006, 26(7): 776-780.
|
[32]
|
Beaugerie, L., Brousse, N., Bouvier, A.M., et al. (2009) Lymphoproliferative Disorders in Patients Receiving Thiopurines for Inflammatory Bowel Disease: A Prospective Observational Cohort Study. The Lancet, 374, 1617-1625.
https://doi.org/10.1016/S0140-6736(09)61302-7
|
[33]
|
Caballero, D. (2019) EBV & lymphoma. HemaSphere, 3, 68. https://doi.org/10.1097/HS9.0000000000000274
|
[34]
|
申艳丽, 张安兴, 罗娟, 缪应雷. 硫唑嘌呤治疗炎症性肠病发生淋巴瘤的风险研究进展[J]. 中国当代医药, 2020, 27(5): 19-22.
|
[35]
|
Siegel, C.A., Finlayson, S.R.G., Sands, B.E. and Tosteson, A.N.A. (2012) Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn’s Disease in a Decision Analytic Model. Clinical Gastroenterology and Hepatology, 10, 46-51. https://doi.org/10.1016/j.cgh.2011.09.017
|
[36]
|
Holmer, A. and Singh, S. (2019) Overall and Comparative Safety of Biologic and Immunosuppressive Therapy in Inflammatory Bowel Diseases. Expert Review of Clinical Immunology, 15, 969-979.
https://doi.org/10.1080/1744666X.2019.1646127
|
[37]
|
Khanna, R. and Feagan, B.G. (2015) Safety of Infliximab for the Treatment of Inflammatory Bowel Disease: Current Understanding of the Potential for Serious Adverse Events. Expert Opinion on Drug Safety, 14, 987-997.
https://doi.org/10.1517/14740338.2015.1029915
|
[38]
|
D’Haens, G., Reinisch, W., Colombel, J.-F., et al. (2017) Five-Year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn’s Disease Treated with Infliximab [Remicade®] or Conventional Therapy. Journal of Crohn’s & Colitis, 11, 680-689. https://doi.org/10.1093/ecco-jcc/jjw221
|
[39]
|
杨霞, 肖敏, 吴斌, 吴逢波. 硫唑嘌呤不良反应文献分析[J]. 中国药业, 2020, 29(7): 134-137.
|
[40]
|
Odahara, S., Uchiyama, K., Kubota, T., et al. (2015) A Prospective Study Evaluat-ing Metabolic Capacity of Thiopurine and Associated Adverse Reactions in Japanese Patients with Inflammatory Bowel Disease (IBD). PLOS ONE, 10, e137798. https://doi.org/10.1371/journal.pone.0137798
|
[41]
|
徐天铭, 李景南, 钱家鸣, 杨红. 硫唑嘌呤治疗疑诊炎症性肠病所致严重感染1例报告[J]. 中国实用内科杂志, 2018, 38(3): 256-257.
|
[42]
|
丁辉, 钱家鸣, 单科曙. 硫唑嘌呤治疗炎症性肠病的不良反应分析[J]. 临床消化病杂志, 2011, 23(1): 40-42, 47.
|